Research programme: antibody therapeutics - FairJourney Biologics/IONTAS
Latest Information Update: 28 Dec 2024
At a glance
- Originator FairJourney Biologics; IONTAS; Pandion Therapeutics
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for research development in Autoimmune-disorders in Portugal
- 28 Dec 2024 No recent reports of development identified for research development in Autoimmune-disorders in United Kingdom
- 28 Dec 2024 No recent reports of development identified for research development in Autoimmune-disorders in USA